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Abstract
Background and Aims: In type 2 diabetes mellitus, disease-related complications have a considerable eﬀect
on the quality of life. We studied the inﬂuence of cardiovascular disease on quality of life in type 2 diabetic
patients in a longitudinal design. We also studied whether quality of life in any way predicts the manifes-
tation of cardiovascular disease. Materials and methods: A prospective cohort study from April 1996 to
October 1999. In 1996 and 1999 all known type 2 diabetics from the population of Urk, the Netherlands,
were invited by their general practitioners (GPs) for extensive check-up. In both years quality of life was
assessed using the generic RAND-36 and the disease-speciﬁc Diabetes Health Proﬁle (DHP). In the inter-
mediate period, cardiovascular morbidity and mortality were registered by the GPs. Results: In 1996, 281
patients were examined and 248 (88.3%) persons completed the questionnaires. After 3 years 189 persons
(67.3%) were re-examined and 161 (85.2%) handed in the questionnaire. When compared to diabetics
without cardiovascular disease, diabetics with cardiovascular disease had a lower quality of life. Multiple
regression analysis showed that contracting cardiovascular disease negatively aﬀects the RAND-36 di-
mensions ‘social functioning’, ‘vitality’ and ‘health change’. Cox’s regression analysis showed a negative
relation between the RAND-36 dimensions ‘physical functioning’, and time to the manifestation of car-
diovascular disease. The DHP appeared not to be suitable to measure quality of life in relation to cardio-
vascular disease. Conclusions: In type 2 diabetics, cardiovascular disease has a negative eﬀect on quality of
life. A decreased quality of life is associated with a short-term manifestation of cardiovascular disease.
Key words: Cardiovascular diseases, Cross-sectional study, Longitudinal studies, Netherlands, Non-insulin
dependent diabetes, Primary health care, Quality of life
Introduction
Diabetes mellitus type 2 is a chronic disease and an
important cause of increased morbidity and early
mortality. Diabetics have an increased risk for
microvascular complications such as diabetic ret-
inopathy, nephropathy and neuropathy. More-
over, when compared with non-diabetics, type 2
diabetics have two to four times greater risk for
macrovascular complications [1–3].
In order to objectively evaluate the conse-
quences of a chronic disease, the term ‘quality of
life’ is used [4–8]. The term quality of life reﬂects
the manner in which the patient experiences life,
and as such is important when trying to under-
stand the inﬂuence of a disease on a person’s life.
In the ﬁeld of health-related quality of life, in-
struments have been developed in the form of
questionnaires that can be distinguished in gener-
al/generic and disease-speciﬁc.
Assessment of ‘quality of life’, and the changes
therein, is used as a manner to evaluate clinical
research and quality of care in diabetics [9, 10].
Persons with diabetes mellitus experience a lower
quality of life than persons without the disease
[10–14]. Persons with diabetes have a quality of life
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249comparable to persons having a chronic disease
such as epilepsy and chronic back pain, but have a
better quality of life than persons with heart
problems, arthritis, multiple sclerosis, CVA or
chronic lung problems [10, 15].
In diabetics, a number of factors are associated
with a decreased quality of life. Important vari-
ables are old age, duration of disease, obesity, in-
sulin therapy, and (severity of) complications [10,
16]. Although the study-results vary with regard to
the relation between quality of life, gender, meta-
bolic control and type of therapy, the relation with
complications is consistent [10, 17–19]. Vascular
and non-vascular comorbidity are considered to be
the most important predictors of decreased quality
of life in type 2 diabetics [10–14, 16, 19–23]. Of
these non-vascular comorbid conditions especially
psychiatric disorders, such as depression and
anxiety disorders have a considerable impact on
the quality of life [24–27]. Since the rate of car-
diovascular disease in type 2 diabetes is high, their
inﬂuence on quality of life is of major importance.
Although various studies show that cardiovas-
cular disease is an important cause of morbidity
and mortality in diabetes, there have been few
longitudinal studies on the relation between car-
diovascular disease and quality of life in type 2
diabetics. One study performed by Wandell et al.
[28] looked at the health-related quality of life in
mainly type 2 diabetic subjects over a 3-year pe-
riod in Sweden. They found a signiﬁcant decrease
in ‘physical functioning’ and a relation between
deterioration in health and ‘sleepp roblems’.
Hanestad and Albrektsen [29] examined the sta-
bility of self-reported quality of life over a 1-year
period in type 1 diabetics in Norway. They found
that the stability of quality of life was high and not
signiﬁcantly inﬂuenced by life events.
The aim of our research was to study the eﬀect
of cardiovascular disease on the health-related
quality of life in type 2 diabetics, and to research
whether a lower quality of life predisposes to an
early manifestation of cardiovascular disease.
In this paper we will answer the following
questions:
1. Which factors are associated with quality of life
in a cross-sectional study?
2. How does cardiovascular disease inﬂuence
quality of life in a longitudinal study?
3. Is decreased quality of life associated with the
short-term manifestation of cardiovascular
disease?
Methods
Population
This study was carried out during March 1996 and
October 1999 in type 2 diabetics on Urk. Urk is a
former island in the Netherlands with approxi-
mately 15,000 inhabitants. Since 1939 it is con-
nected to the mainland, due to reclamation of
land. The study was performed during the annual
check-upfor subjects with typ e 2 diabetes mellitus
according to the guidelines of the Dutch College of
General Practitioners [30]. The patients invited
were all known type 2 diabetics and registered as
such in the records of the general practitioners
(GPs). Identiﬁcation of type 2 diabetes is done
according to criteria given in the above-mentioned
guidelines [30]. In 1996 the prevalence of diabetes
mellitus type 2 in the population of Urk was (334/
14,934) 2.2%. Due to the high birthrate the pop-
ulation is relatively young when compared to the
general Dutch population [31]. The mean age of
the men and women from Urk is, respectively, 9.1
and 10.1 years less compared to the rest of the
adult Dutch population. On Urk, check-up of the
type 2 diabetic patients is performed by the GPs,
and, if required, the GP will also initiate insulin
therapy.
Study design
In 1996 and 1999 all 334 known diabetics on Urk
were invited to visit the practice for a compre-
hensive check-up. Enclosed with the invitation for
the examination and the explanation regarding the
study, the patient received two questionnaires, the
RAND-36 and the DHP.
Prior to their visit to the practice, (fasting) blood
was taken for laboratory examination, and a
sample of morning urine was handed in. The GP
registered general data, disease-speciﬁc informa-
tion and data on cardiovascular morbidity. A
general physical examination and a check-up of
the peripheral vascular system was performed. At
250their next visit to the practice, all participants were
informed of their individual laboratory results.
In the period between the 1996 and 1999 studies,
cardiovascular morbidity and mortality was
checked using the registration system of the GP.
Of all persons examined in 1996, the GP’s data and
the letters from the specialists were checked for
episodes of cardiovascular disease. Both morbidity
and mortality were recorded.
For cardiovascular disease, a distinction was
made between coronary heart failure (acute myo-
cardial infarction, PTCA, coronary artery bypass
surgery (CABG)) and cerebrovascular disease
(TIA, CVA), and other cardiovascular diseases
(heart failure, peripheral vascular disease, surgery
of the peripheral vascular system, cardiac dys-
rhythmias). Comorbidity was deﬁned as the pres-
ence of any number of the following diseases:
COPD, other lung diseases, serious back problems,
rheumatism or articular complaints, cancer, dis-
eases of the nervous system, endocrinological dis-
eases and psychiatric diseases.
Questionnaire on quality of life
In this study we used two health-related quality of
life questionnaires, one generic (RAND-36) and
one disease-speciﬁc (DHP) [32, 33]. For both tests,
Dutch validated versions were available [34, 35].
The RAND-36 contains eight dimensions:
‘physical functioning’, ‘social functioning’, ‘role
impairment due to physical and emotional prob-
lems’, ‘mental health’, ‘vitality’, ‘pain’ and ‘general
health perception’. One item measures ‘health
change’. From the various dimensions a physical
and mental component score can be calculated
[36]. These component scores give further insight
into the subscales. The RAND-36 is a valid, reli-
able and responsive generic questionnaire. The
RAND-36 makes it possible to distinguish be-
tween chronically ill and healthy persons; fur-
thermore, the test is suited for use in a general
population [32, 37]. The questionnaire seems to be
sensitive to changes in number and severity of
complications in diabetics [5]. The Diabetes Health
Proﬁle (DHP) is a disease-speciﬁc questionnaire
developed to identify psychological and behavio-
ural problems in insulin-dependent diabetics [33].
The DHP contains three dimensions ‘psychosocial
distress’, ‘barriers to activity’ and ‘disinhibiting
eating’.
The dimension ‘psychosocial distress’ comprises
important components of psychological dysfunc-
tioning, such as vulnerability to stress and emo-
tional instability. The dimension ‘barriers to
activity’ reﬂects the restrictions in activities due
to limitations in behaviour, social isolation due to
diabetes, experienced psychological disturbances,
and anxiety reducing and avoidance behaviour. Of
the 13 items, one question was removed from the
questionnaire since it concerned a speciﬁc question
on insulin injections. The dimension ‘disinhibiting
eating’ contains the disinhibited eﬀects due to eat-
ing-habit-related emotions. Goddijn et al. [34] have
validated the DHP questionnaire in a groupof typ e
2 diabetics referred for insulin therapy. For each
dimension the item scores are coded, added up, and
then transformed into a scale from 0 (worst health)
to 100 (best health). When values were missing, a
personal average per dimension was calculated
from the items that had been entered.
Analysis
Statistical analyses were done with SPSS for
Windows [38]. As multiple comparisons were
performed, a p-value of 0.01 was used as level of
signiﬁcance to compensate for multiple testing ef-
fects. We ﬁrst studied the relation between the
various dimensions of the quality of life ques-
tionnaires, and the demographic and clinical
variables (baseline data, 1996). For the continuous
variables the Spearman correlation coeﬃcient was
used, and for nominal variables the t-test for
normal distributed variables, and the Mann–
Whitney U-test for the non-normal distributed
variables. Multiple linear regression was used to
study variables associated (p<0.05) with one or
more dimensions for their independent eﬀect.
The analysis of the inﬂuence of cardiovascular
disease on quality of life was done in persons who
had ﬁlled out a questionnaire in 1996 as well as in
1999. Previously, we established which baseline
variables and changes in variables were indepen-
dently associated (p < 0.05) with a change in
quality of life.
The associated (p < 0.05) variables from the
regression analyses were used for the analysis of
251the eﬀect of cardiovascular disease on the change
in quality of life. This was done with the GLM
univariant procedure with the 1999 quality of life
dimension score as independent variable, and the
1996 dimension score and associated (p < 0.05)
variables as covariants. Whether or not an episode
of cardiovascular disease had been experienced
during the course of the study was added as a
factor in the analysis.
The analysis of the predictive value of the
quality of life score for short-term manifestation of
cardiovascular disease was done with Cox’s re-
gression analysis; here the period until cardiovas-
cular disease was used as the dependent variable,
and the dimension score for the quality of life and
the associated (p < 0.05) variables as covariant.
As covariants, baseline variables were chosen that
were associated with the quality of life dimensions
in the multiple linear regression analysis. If a
person experienced more than one episode of
cardiovascular disease during the course of the
study, only the ﬁrst episode of cardiovascular
disease was used in the analysis.
Results
In 1996, 281 (84.1%) of the 334 invited type 2
diabetics were examined, of whom 248 (88.3%)
returned the questionnaire. The average age was
67.4 (range: 22–96 years). From the 281 persons
examined in 1996, 189 (67.3%) were also examined
in 1999. In total, 49 (17.4%) persons died during
the study period, and 43 (15.3%) persons did not
want to co-operate in the study of 1999. In the
latter group, 33 persons did not respond after re-
peated notice, ﬁve persons indicated that they were
under specialist care, and ﬁve persons were not
able to participate due to terminal illness.
Table 1 shows the baseline characteristics of the
population examined in 1996. The baseline data
are divided in: (A) the groupof p atients that was
Table 1. Baseline characteristics for the patients examined in 1996
Baseline data 1996 Total group
(N=281)
GroupA
(N=189)
GroupB
(N=43)
GroupC
(N=49)
Age in years (SD) 67.4 (11.8) 65.2 (11.5) 67.7 (11.9) 75.8 (8.9)**
Duration of diabetes (SD) 8.1 (7.15) 7.4 (6.7) 8.0 (6.8) 11.1 (8.2)*
Males (%) 146 (52.0) 101 (53.4) 21 (48.8) 24 (49.0)
Smokers (%) 64 (23.7) 44 (23.5) 10 (23.8) 10 (24.4)
Systolic blood pressure in mmHg (SD) 151.1 (22.9) 150.0 (22.5) 153.6 (24.8) 153.3 (22.6)
Diastolic blood pressure in mmHg (SD) 83.4 (11.9) 83.3 (11.0) 85.3 (14.7) 81.6 (12.3)
Total cholesterol in mmol/l (SD) 6.3 (1.33) 6.4 (1.3) 6.1 (1.5) 5.9 (1.2)
HDL-cholesterol in mmol/l (SD) 1.2 (0.32) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3)
Triglycerides in mmol/l (SD) 2.4 (3.28) 2.7 (3.8) 1.7 (1.1) 2.1 (1.3)
Body Mass Index in kg/m
2 (SD) 28.6 (4.4) 29.0 (4.2) 28.7 (5.5) 26.5 (3.0)*
HbA1c in % (SD) 7.6 (2.24) 7.5 (2.0) 7.7 (2.2) 7.9 (2.1)
Fasting blood-glucose in mmol/l (SD) 9.9 (3.22) 10.1(3.1) 9.9 (3.4) 9.3 (3.2)
Albumin/creatinine ratio (SD) 14.4 (39.7) 11.6 (32.3) 21.7 (51.3) 18.6 (42.4)
Co morbidity (SD) 1.3 (1.62) 1.0 (1.4) 1.3 (1.7) 2.2 (2.1)**
No diabetes medication (%) 66 (23.5) 38 (20.1) 18 (41.9)* 10 (20.4)
Oral bloodglucose lowering medication (%) 215 (76.5) 109 (57.7) 16 (37.2) 24 (49.0)
Insulin therapy (%) 73 (26.0) 48 (25.4) 10 (23.3) 15 (30.6)
Conﬁrmed diabetic retinopathy (%) 10 (5.5) 9 (4.8) 0 1 (2.0)
Foot problems (ulcers or amputation) (%) 9 (3.5) 5 (2.6) 1 (2.3) 3 (6.1)
Cardiovascular disease (%) 99 (35.6) 62 (32.8) 11 (25.6) 26 (53.1)*
Coronary heart disease 58 (20.9) 40 (21.3) 5 (27.7) 13 (20.9)
CVA 25 (9.1) 15 (8.1) 2 (4.8) 8 (16.7)
Other cardiovascular diseases 53 (19.1) 26 (13.8) 9 (22.0) 18 (37.5)**
GroupA (re-examined in 1999); groupB (not examined in 1999); and groupC (deceased during the course of the study).
*p < 0.01, **p < 0.001; Compared to group A; Independent t-test for continuous variables and v
2-test for dichotomous variables.
252examined both in 1996 and in 1999, (B) the group
that was examined in 1996 but did not want to co-
operate in 1999, and (C) the group that was ex-
amined in 1996, but died during the course of the
study. Table 1 also shows that, compared to the
groupthat was re-examined in 1999, the p ersons
who died during the course of the study were at
baseline older, had had diabetes for a longer pe-
riod of time, had a lower body mass index (BMI),
higher comorbidity, and had experienced more
episodes of cardiovascular disease.
The baseline data of the groupthat did not
want to co-operate in 1999, did not diﬀer from
the groupthat did co-op erate, excep t for the
higher percentage that was not using diabetes
medication.
In 1996, we received 248 (88.3%) question-
naires, of which 215 (86.7%) had been fully com-
pleted. There were no signiﬁcant diﬀerences in the
base-line variables between the persons who did
return the questionnaire and those who did not
(data not shown).
From the 189 persons examined in 1999, we
received 161 (85.2%) questionnaires, of which 140
(86.9%) were fully completed. Seven persons did
not complete the questionnaire in 1996, but did so
in 1999. Table 2 shows that the baseline quality of
life scores for persons who did not want to co-
operate in 1999 are comparable to the baseline
quality of life scores for the groupthat did com-
plete the questionnaire in 1999. No signiﬁcant
diﬀerences were found. The RAND-36 dimension
scores ‘physical functioning’, ‘social functioning’,
‘limitations due to a physical problem’ and ‘gen-
eral health perception’ are signiﬁcantly lower in
the groupof p ersons that died during the course of
the study compared to the group that was re-ex-
amined. No signiﬁcant diﬀerences were found be-
tween the subgroups for the DHP-scores.
During the 3-year course of the study 90
(36.3%) patients experienced one or more cardio-
vascular events. Of these, 52 (21.0%) experienced a
coronary heart disease, 17 (6.9%) a cerebrovas-
cular disease and 55 (22.2%) another cardiovas-
cular disease.
Baseline variables associated with quality of life
In Table 3 the results of the multiple linear re-
gression analysis show the association of general
and disease-speciﬁc variables with the dimensions
of the RAND-36 and DHP. Older subjects with
type 2 diabetes mellitus have a lower score on
the dimension ‘physical functioning’ (from the
RAND-36) but a higher score on the dimensions
of the DHP.
Table 2. Baseline quality of life scores for dimensions of the RAND-36 and DHP in 1996
Questionaire dimension Total
(N = 248)
GroupA
(N = 174)
GroupB
(N = 38)
GroupC
(N = 36)
RAND-36
Physical functioning (10 items) 52.2 (34.3) 57.0 (33.1) 46.9 (34.5) 33.7 (33.4)**
Social functioning (two items) 66.3 (24.8) 70.0 (21.8) 62.8 (28.1) 51.3 (29.3)**
Role impairment (due to physical problem) (four items) 61.3 (42.3) 65.2 (41.0) 60.4 (44.1) 40.8 (42.3)*
Role impairment (due to emotional problem) (three items) 71.0 (40.3) 72.4 (39.8) 78.1 (37.5) 54.3 (43.5)
Pain (two items) 71.6 (29.7) 74.1 (28.5) 67.9 (32.9) 62.7 (30.8)
Mental health (ﬁve items) 58.3 (58.3) 58.8 (20.8) 61.5 (22.1) 52.6 (24.3)
Vitality (four items) 47.7 (23.5) 49.4 (23.1) 46.4 (24.1) 40.2 (23.9)
General health perception (ﬁve items) 44.0 (23.9) 47.2 (23.1) 37.4 (24.0) 35.3 (24.4)*
Health change 47.2 (22.4) 48.7 (21.0) 42.1 (25.4) 45.6 (25.0)
Physical components (six dimensions) 58.4 (23.7) 61.6 (22.4) 54.7 (25.0) 45.1 (24.9)*
Mental component (ﬁve dimensions) 59.3 (20.6) 60.8 (20.2) 60.1 (20.4) 49.8 (21.9)
DHP
Psychosocial distress (14 items) 87.3 (9.1) 87.3 (8.7) 87.4 (10.6) 87.3 (9.4)
Barriers to activity (12 items) 75.6 (12.5) 75.3 (12.0) 77.1 (13.9) 75.2 (13.7)
Disinhibiting eating (ﬁve items) 71.6 (24.0) 68.4 (23.7) 79.2 (26.3) 79.0 (19.4)
GroupA (re-examined in 1999); groupB (not examined in 1999); and groupC (deceased during the course of the study).
*p < 0.01, **p < 0.001; Compared to group A; t-test.
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254The number of other diseases (comorbidity) has
a signiﬁcantly negative association with the di-
mensions ‘physical functioning’, ‘pain’ and the
physical component score.
The BMI is negatively associated with the di-
mension ‘physical functioning’ and ‘disinhibiting
eating’.
The duration of having diabetes is negatively
associated with the dimensions ‘physical function-
ing’, ‘role impairment due to physical problem’ and
the physical component score. A higher HbA1c is
associated with reduced score on ‘physical func-
tioning’. In the multivariate analysis, the variables
gender, oral blood-glucose-lowering medication,
insulin therapy, albumin/creatinine ratio, foot
problems and diabetic retinopathy were not sig-
niﬁcantly associated with one or more dimensions
of the RAND-36 and DHP questionnaire.
At baseline 99 (35.6%) patients were known to
have a cardiovascular disease. These patients with
cardiovascular disease have a lower quality of life
score in several dimensions of the RAND-36 at
baseline. After correction for the inﬂuence of other
variables, the dimension scores of the RAND-36
for cardiovascular disease range between  6:1 and
 16:6. The scores for ‘physical functioning’, ‘vi-
tality’ and ‘general health perception’ as well as the
physical and the mental component score of the
RAND-36 are signiﬁcantly lower in persons that
experienced a cardiovascular disease. The scores
on the DHP questionnaire are not signiﬁcantly
diﬀerent for persons with and without cardiovas-
cular disease. Figure 1 shows the unadjusted
transformed scores of the RAND-36 and the DHP
per dimension for persons with and without ex-
perienced episodes of cardiovascular disease.
The inﬂuence of cardiovascular disease on quality
of life
Of the 154 persons who completed the quality of
life questionnaires in 1996 and 1999, 47 (30.5%)
experienced one or more episodes of cardiovascu-
lar disease during the three years of the study.
Table 4 shows the results of the eﬀect of cardio-
vascular disease on the various dimensions of the
quality of life. The variables in the footnote of
Table 4 appear to be either associated (p < 0.05)
with one or more of the baseline quality of life
scores or with the diﬀerence in scores between the
quality of life dimensions in 1996 and 1999 (anal-
ysis not shown). The multivariate analysis shows
for all RAND-36 dimensions a lower score rang-
ing from  4:4t o 12:7. There is a signiﬁcantly
negative eﬀect due to episodes of cardiovascular
disease on the RAND-36 dimension ‘role impair-
ment due to a physical problem’ (b ¼  10:4,
p ¼ 0.01), ‘mental health’ (b ¼  10:9, p ¼ 0.01),
and ‘health change’ (b ¼  10:0, p ¼ 0.01).
The negative eﬀects on the dimensions ‘social
functioning’ (b ¼  10:4, p ¼ 0.02), ‘vitality’ (b ¼
 9:2, p ¼ 0.02), ‘general health perception’ (b ¼
 8:8, p ¼ 0.03) and the mental componentscore
(b ¼  8:0, p ¼ 0.04), are borderline signiﬁcant.
Figure 1. Diﬀerence in baseline quality of life score on dimensions of RAND-36 and DHP for type 2 diabetes patients with and
without cardiovascular disease (Independent t-test, p-value).
255The dimension scores of the DHP for cardiovas-
cular disease are between  0:8a n d 4:1 lower for
persons with experienced cardiovascular disease,
but none of them are signiﬁcant. There seems to be
no eﬀect of cardiovascular disease on quality of life
as measured by the DHP.
During the course of the study, 29 (18.8%)
persons experienced coronary heart disease. Cor-
onary heart disease was shown to cause a decrease
in quality of life in the various dimensions of the
RAND-36, but not reaching the level of signiﬁ-
cance of p ¼ 0.01. Nine (5.8%) persons experi-
enced a cerebrovascular disease during the course
of the study. Cerebrovascular disease appeared to
give decrease in all dimensions of the RAND-36 of
which ‘mental health’ (b ¼  29:2, p ¼ 0.00) and
‘vitality’ (b ¼  19:0, p ¼ 0.01) are signiﬁcant. Al-
though there was a decrease in some of the di-
mensions of the RAND-36 due to the remaining
cardiovascular disease (30 persons, 19.5%) none of
them reached the level of signiﬁcance of p ¼ 0.01.
For coronary heart disease, cerebrovascular dis-
ease as well as the remaining cardiovascular dis-
eases there is no signiﬁcant eﬀect on the
dimensions of the DHP measured.
The development of diabetic retinopathy and
foot problems, initiation of insulin therapy, and
changes in HbA1c and the albumin/creatinin ratio
did not show a signiﬁcant change in the quality of
life score measured by the RAND-36 and the
DHP.
Predictive value of quality of life score on the
manifestation of cardiovascular disease
For all 248 persons who completed the question-
naire in 1996 it was possible to trace whether they
had experienced a cardiovascular disease in the
period 1996–1999; in total 90 (36.3%) persons
experienced one or more episodes of cardiovascu-
lar disease; 52 (21.0%) persons experienced a
coronary heart disease, of which seven died; 17
(6.9%) persons experienced a cerebrovascular
disease, of which two persons died; 55 (22.2%)
persons experienced an other cardiovascular dis-
eases, of which 13 died. Table 5, which gives the
results of the Cox’s regression analysis, shows that
the RAND-36 dimension ‘physical functioning’
(Exp(B) ¼ 0.989, p ¼ 0.009), is signiﬁcantly pre-
dictive for imminent cardiovascular disease. The
Table 4. Longitudinal impact of cardiovascular disease and subtypes of cardiovascular disease on the dimensions of quality of life
measured with the RAND-36 and DHP, using data of 1996 and 1999 (GLM univariate analysis – regression coeﬃcients)
Questionnaire dimension Total CVD (N = 47) CHD (N = 29) CVA (N = 9) OCVD (N = 30)
RAND-36
Physical functioning  4.35  3.46  5.35  7.15
Social functioning  10.37  9.21  11.87  1.09
Role impairment (physical problem)  12.67  17.68  16.09 1.87
Role impairment (emotional problem)  11.77  4.61  12.13  1.69
Pain  4.68  5.59  0.75 2.33
Mental health  10.91  4.75  29.16**  5.98
Vitality  9.16*  6.46  18.96  5.01
General health perception  8.83  1.81  14.41  10.93
Health change  10.03*  9.14  11.98 1.36
Physical component  4.84  3.45  9.15  0.72
Mental component  7.95  2.88  13.20  3.71
DHP
Psychosocial distress  1.93 0.84  5.14  0.94
Barriers to activity  0.82  0.19  3.02  1.90
Disinhibiting eating  4.10  0.75  2.73  5.98
This model has been corrected for the following baseline variables: sex, age, duration of diabetes, co-morbidity (number), insulin
therapy, use of blood-glucose-lowering medication, previous cardiovascular disease, BMI, HbA1c, albumin/creatinine ratio,
development of diabetic retinopathy, foot problems, initiation of insulin therapy, change in HbA1c, change in albumin/creatinine ratio,
baseline dimension score on quality of life questionnaire.
*p < 0.01, **p < 0.001.
CVD – cardiovascular disease; CHD – coronary heart disease; CVA – cerebrovascular disease; OCVD – other cardiovascular diseases.
256dimensions ‘vitality’ (Exp(B) ¼ 0.989, p ¼ 0.039)
and ‘general health perception’ (Exp(B) ¼ 0.987,
p ¼ 0.016) are borderline signiﬁcant in predicting
cardiovascular disease. None of the DHP dimen-
sions has a value that is signiﬁcantly predictive for
cardiovascular disease. When analysing the cate-
gories of cardiovascular disease, the dimensions
‘physical functioning’ (Exp(B) ¼ 0.989, p ¼ 0.045)
and ‘general health perception’ (Exp(B) ¼ 0.985,
p ¼ 0.034) appear to be predictive of imminent
manifestation of coronary heart disease, although
not reaching the level of signiﬁcance. For the
cerebrovascular diseases, the dimension ‘general
health perception’ (Exp(B) ¼ 0.985, p ¼ 0.010) is
signiﬁcantly predictive, and the dimension ‘vitali-
ty’ (Exp(B) ¼ 0.969, p ¼ 0.024) is predictive, but
not reaching the level of signiﬁcance . No dimen-
sion of the RAND-36 or DHP seems to be sig-
niﬁcantly predictive for contracting the other
cardiovascular diseases.
Discussion
Diabetes mellitus has a marked inﬂuence on
quality of life. Symptoms, therapy, and accompa-
nying complications aﬀect various aspects of the
quality of life [10]. Since cardiovascular diseases
are the most prevalent complication in diabetes
mellitus type 2, this study looks into the speciﬁc
inﬂuence that cardiovascular diseases have on
quality of life.
The cross-sectional analysis of the baseline data
show that subjects with type 2 diabetes mellitus
with a cardiovascular disease score between 6.1 and
16.6 points lower on all dimensions of the RAND-
36 (0–100 scale). After correction for other factors,
it appears that patients with cardiovascular dis-
eases score signiﬁcantly lower on the dimensions
‘physical functioning’, ‘social functioning’, ‘vitali-
ty’, ‘general health perception’, ‘health change’ as
well as the physical and the mental component
score. With the aid of 3-year follow-updata, the
eﬀect of cardiovascular disease on the dimensions
of quality of life was studied longitudinally in type
2 diabetics. Adjusted for other variables, cardio-
vascular disease gives a 4.4–12.7 points lower score
on the RAND-36 dimensions (0–100 scale). Car-
diovascular diseases have a signiﬁcant negative
eﬀect on the RAND-36 dimensions , ‘role impair-
ment due to a physical problem’, ‘mental health’,
and ‘health change’. Cerebrovascular diseases
cause a signiﬁcant decrease in the dimensions
‘mental health’ and ‘vitality’.
Table 5. Predictive value of baseline quality of life scores on the short-term manifestation of cardiovascular disease and subtypes of
cardiovascular disease (Cox’s regression, Exp(B) (99% CI))
Questionnaire dimension Total CVD (N = 90) CHD (N = 52) CVA (N = 17) OCVD (N = 55)
RAND-36
Physical functioning 0.989 (0.978–0.999)* 0.989 (0.975–1.003) 0.985 (0.959–1.012) 0.989 (0.974–1.003)
Social functioning 0.996 (0.985–1.007) 1.001 (0.985–1.016) 0.988 (0.960–1.016) 0.995 (0.981–1.010)
Role impairment (physical problem) 0.995 (0.988–1.002) 0.998 (0.988–1.008) 0.998 (0.981–1.016) 0.997 (0.987–1.006)
Role impairment (emotional problem) 0.996 (0.988–1.003) 0.997 (0.988–1.007) 0.998 (0.981–1.016) 0.998 (0.988–1.008)
Pain 0.995 (0.984–1.005) 0.998 (0.984–1.011) 1.002 (0.976–1.029) 0.990 (0.974–1.001)
Mental health 0.996 (0.982–1.010) 1.010 (0.991–1.029) 0.981 (0.950–1.013) 0.992 (0.974–1.010)
Vitality 0.989 (0.976–1.003) 0.997 (0.980–1.014) 0.969 (0.934–1.002) 0.996 (0.978–1.014)
General perception of health 0.987 (0.973–1.001) 0.985 (0.965–1.001) 0.960 (0.920–0.999)* 0.991 (0.973–1.010)
Health change 0.995 (0.982–1.008) 0.999 (0.982–1.015) 0.981 (0.950–1.012) 1.000 (0.983–1.018)
Physical component 0.990 (0.976–1.004) 0.996 (0.978–1.014) 0.983 (0.950–1.016) 0.993 (0.974–1.012)
Mental component 0.989 (0.973–1.005) 0.997 (0.978–1.017) 0.979 (0.945–1.014) 0.996 (0.974–1.018)
DHP
Psychosocial distress 0.993 (0.959–1.028) 1.019 (0.971–1.069) 0.997 (0.910–1.091) 0.978 (0.938–1.019)
Barriers to activity 0.996 (0.973–1.019) 1.014 (0.980–1.049) 1.001 (0.947–1.058) 0.997 (0.966–1.028)
Disinhibiting eating 0.999 (0.985–1.014) 1.002 (0.983–1.022) 1.016 (0.976–1.057) 0.996 (0.978–1.014)
This model has been corrected for the following base-line variables: sex, age, duration of diabetes, HbA1c, BMI, co-morbidity,
previous episodes of cardiovascular disease.
*p < 0.01.
CVD – cardiovascular disease; CVD – coronary heart disease; CVA – cerebrovascular disease; OCVD – other cardiovascular diseases.
257The RAND-36 dimensions ‘vitality’ and ‘gen-
eral health perception’ are to a considerable extent
negatively inﬂuenced by prior or present cardio-
vascular disease. This can be explained by the fact
that cardiovascular diseases are often accompa-
nied by a loss in ability. This loss inﬂuences the
physical functioning of a patient. According to the
results of this study, cardiovascular diseases also
seem to inﬂuence social and mental functioning.
The cross-sectional data show that subjects with
type 2 diabetes mellitus who have experienced an
episode of cardiovascular disease score lower on
the dimension ‘social functioning’. It is feasible
that these patients are restricted in their social life
by their physical impairments due to the cardio-
vascular disease.
The longitudinal data show that in the groupof
patients that experience an episode of cardiovas-
cular disease, ‘mental health’ is negatively aﬀected.
A cardiovascular event and its long-term conse-
quences are considered to have a major impact on
a person’s mental well-being. Moreover, it should
be noted that in subjects with type 2 diabetes
mellitus, psychological symptoms and long-stand-
ing psychiatric disorders are more common than in
healthy controls and psychiatric disorders are
major predictors of a lower quality of life [25, 27].
A decreased score on the RAND-36 dimension
‘physical functioning’, in subjects with type 2 dia-
betes mellitus appears to be independently related
to the short-term manifestation of cardiovascular
disease. A decreased score on the dimension
‘general health perception’ is predictive for the
short-term manifestation of cerebrovascular dis-
eases. An explanation for these results may be that
prior to the episode of cardiovascular disease,
patients already experience symptoms or com-
plaints that negatively inﬂuence their quality of
life. This explanation is supported by the fact that
the dimensions with a predictive value contain the
physical aspect of quality of life, whereas the
mental components do not have a predictive value.
Therefore quality of life as subjective health per-
ception can also be explained as the summary
function of functional status and general health.
Another ﬁnding that supports the predictive value
of quality of life is found in the baseline quality of
life scores of the subgroupof diabetic p atients who
died during the study period. Compared to the
survivors they had a lower quality of life at base-
line. This can at least partly be explained by the
diﬀerence in age, duration of diabetes, cardiovas-
cular disease and comorbid conditions. However,
the diﬀerence supports the ﬁnding that a lower
self-rated health is predictive of mortality. This has
been reported by various studies in the general
population as well as in late-onset diabetes [39–43].
Considering the association between quality of
life and the chance of contracting cardiovascular
disease, an evaluation of the aspect of quality of
life in subjects with type 2 diabetes mellitus may be
useful for calculating the risk of cardiovascular
disease. However, the use of the existing compre-
hensive quality of life questionnaires is practically
not feasible. A small number of direct questions
enabling a general evaluation of quality of life
combined with questions directed at speciﬁc
symptoms combined with objective parameters
may well be suﬃcient to evaluate the risk.
Various cross-sectional studies have shown that
macrovascular complications in diabetics are as-
sociated with a lower quality of life [11, 13, 16, 20].
A study by De Grauw et al. [44] shows that in type
2 diabetes next to the inﬂuence of diabetes itself,
cardiovascular morbidity has a major eﬀect on the
functional health status, as measured by the sick-
ness impact proﬁle (SIP). Klein et al. [20] conclude
that for younger onset diabetics as well as for late-
onset diabetics, the presence of cardiovascular
disease is signiﬁcantly related to a lower quality of
life. Naess et al. [21] conclude in their study that
the lower quality of life in subjects with type 2
diabetes mellitus can be largely explained by the
relatively frequent presence of cardiovascular
problems in diabetics. The study by Mitchell et al.
[22] shows that vascular complications explain to a
large extent the physical and psychological re-
strictions in diabetics.
To our knowledge, this is the ﬁrst study analy-
sing the impact of cardiovascular disease in type 2
diabetes mellitus in a longitudinal design. No
previous studies into the predictive value of a de-
crease in quality of life on the manifestation of
cardiovascular disease in type 2 diabetes mellitus
were found. In a comparable study, Davis et al.
[45] studied the predictive value of a number of
variables on the survival of type 2 diabetics. The
psychosocial impact of having diabetes appeared
to be one of the major predictive factors for
mortality.
258Disease-speciﬁc questionnaires are used to ex-
plore relationships within the disease, whereas
generic questionnaires measure quality of life more
generally. It can be assumed that cardiovascular
disease has a greater impact on global quality of
life than on diabetes-related quality of life. Con-
sequently, changes in quality of life due to car-
diovascular disease are more likely to be found in
models based on generic questionnaires. In this
study both a generic and a disease-speciﬁc quality
of life questionnaire were used.
We thus expected that the generic RAND-36
would be more sensitive to changes due to long-
term complications and the disease-speciﬁc DHP
more to diabetes-speciﬁc changes. The results of
our study show that the RAND-36 is able to
measure the inﬂuence caused by cardiovascular
complications. The DHP did not measure any
change caused by cardiovascular complications.
The study by Goddijn et al. [34] shows that the
DHP is also not sensitive for measuring the inﬂu-
ence of complications and changes in complica-
tions.
Furthermore, it also appears that more diabetes-
speciﬁc features are associated with the generic
RAND-36 than with the DHP. Duration of dia-
betes, HbA1c, albumin-creatinin ratio, diabetes
medication or diabetes-related complications did
not show any association with the DHP. Duration
of diabetes and HbA1c did show associations with
the dimensions of the RAND-36. In the study of
Goddijn et al. [34], the DHP was shown to be
sensitive to changes in quality of life after initia-
tion of insulin therapy. Furthermore, in the study
of Whitty et al. [46], no signiﬁcant improvement
was found in the DHP dimensions after initiation
of insulin therapy, whereas the dimensions of the
SF-36 did show signiﬁcant improvement. Ac-
cording to Meadows et al. [33] and Goddijn et al.
[34], the three dimensions of the DHP explain only
a small part of the variance (35 and 32%, respec-
tively). In view of the results with the DHP in the
above-mentioned studies and the results of this
study, the use of the DHP as disease-speciﬁc test
for quality of life in type 2 diabetics cannot be
recommended.
Although the total number of cardiovascular
events in this study is rather high, the frequency of
the diﬀerent subtypes of cardiovascular diseases is
low. Despite the large variation in the quality of
life scores, the number of patients for the subtypes
were not enough to detect signiﬁcant diﬀerences.
Another important restriction of the present study
is the missing data on the quality of life in the
cross-sectional as well as the longitudinal analysis.
Although the baseline variables of the small group
for which no quality of life data were known did
not signiﬁcantly diﬀer, we cannot exclude that this
groupwould evaluate quality of life diﬀerently.
Moreover, a number of people examined during
the 3-year study died; consequently, no longitudi-
nal quality of life data were available for this
groupin which the largest change in quality of life
was to be expected. More frequent measurements
could have yielded more speciﬁc data, but also
more ‘noise’.
Furthermore, a number of persons examined in
1996 did not participate in 1999. The baseline
variables of the groupthat was examined in 1996
only diﬀered by just one aspect from the rest of the
group; they used less blood-glucose-lowering
medication. However, there was a signiﬁcant dif-
ference for the RAND-36 dimension ‘general
health perception’ and the DHP dimension ‘dis-
inhibiting eating’.
Another limitation is that a number of variables
known to be associated with quality of life were
not available, such as civil and socio-economic
status and the presence of symptoms of depres-
sion. Since only the ﬁrst cardiovascular event was
used in the analysis, no calculation could be made
to estimate the eﬀect of more than one experienced
event.
Yet, it may be posed that the results of this
study conﬁrm the observation that cardiovascular
diseases not only have a considerable eﬀect on
morbidity and mortality but also have a major
inﬂuence on quality of life in persons with diabetes
mellitus. This underlines the importance of the
prevention of cardiovascular disease in diabetes
mellitus from the patient’s perspective. It is ad-
visable to use the patient’s perspective to induce
patients to contribute to the prevention of car-
diovascular diseases.
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